Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apellis Pharmaceuticals, Inc. (APLS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer listed on the Nasdaq Global Select Market, Apellis uses filings such as Forms 10-K, 10-Q, 8-K, and others to report on its business, financial condition, risk factors, and material events related to its complement-based therapies SYFOVRE and EMPAVELI/Aspaveli.
In these filings, investors can review detailed information on revenue from SYFOVRE and EMPAVELI, research and development spending for ophthalmology and rare disease programs, and the status of key clinical trials such as GALE and VALIANT. Risk factor and management discussion sections typically describe the scientific and regulatory considerations associated with targeting C3 in geographic atrophy, C3 glomerulopathy, primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria.
Current reports on Form 8-K, such as the Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi), document material definitive agreements that affect Apellis’ economics, including ex-U.S. royalty structures for Aspaveli and related financing consents. These filings help clarify how collaborations and capital arrangements support the company’s commercialization and pipeline strategy.
On Stock Titan, Apellis filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly understand topics like royalty arrangements, cash runway, product revenue trends, and major clinical or regulatory milestones. Users can also review Forms 4 and other insider transaction reports to monitor trading activity by Apellis directors and executives, alongside proxy and governance disclosures that describe compensation and board oversight. This page is a central resource for analyzing the regulatory record behind APLS stock.
Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported a sale of 873 shares of Apellis common stock on January 13, 2026 at a price of $22.1872 per share. According to the filing, this sale was made to cover tax withholding on restricted stock units that were released on January 12, 2026, meaning it was tied to an equity compensation event rather than an open-market discretionary sale. Following this transaction, Chopas beneficially owned 52,595 shares of Apellis common stock in direct ownership.
Apellis Pharmaceuticals, Inc. (APLS) reported an insider tax-related share sale by its Chief Business & Strat Officer, Mark DeLong. On January 13, 2026, DeLong sold 1,780 shares of Apellis common stock at a price of $22.1872 per share. According to the footnotes, these shares were sold solely to cover tax withholding on Restricted Stock Units that were released on January 12, 2026. Following this transaction, DeLong beneficially owned 83,058 shares of Apellis common stock, which includes 893 shares acquired through the company’s employee stock purchase plan on April 30, 2025.
Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, reported a small insider stock sale. On January 13, 2026, he sold 2,277 shares of Apellis common stock at a price of $22.1872 per share. According to the footnote, these shares were sold solely to cover tax withholding on Restricted Stock Units that were released on January 12, 2026.
After this transaction, Deschatelets beneficially owned 1,158,219 shares of Apellis common stock in direct form. The filing is made as a Form 4 by a single reporting person in his capacity as Chief Scientific Officer.
Apellis Pharmaceuticals CEO Cedric Francois, who also serves as a director, reported a sale of common stock. On January 13, 2026, he sold 10,186 shares of Apellis common stock at a price of $22.1872 per share, leaving him with 321,419 shares held directly. The filing explains that this sale was made to cover tax withholding on restricted stock units that were released on January 12, 2026.
In addition to his direct holdings, the filing lists indirect holdings in several trusts: 307,946 shares held by The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares held by The Cedric Francois Irrevocable Trust of 2023, 300,000 shares held by The Francois Grossi Trust, and 234,411 shares held by The Francois-DuBois Educational Trust. For each of these trusts, the filing states that Francois disclaims beneficial ownership of the shares except to the extent of his pecuniary interest.
Apellis Pharmaceuticals' Chief Technical Officer Nur Nicholson reported a sale of company stock. On January 13, 2026, Nicholson sold 2,618 shares of Apellis common stock at a price of $22.1872 per share. According to the disclosure, these shares were sold to cover tax withholding on Restricted Stock Units that were released on January 12, 2026, meaning the transaction was tied to an equity award rather than an open-market discretionary sale of the full grant.
After this tax-related sale, Nicholson beneficially owned 81,046 shares of Apellis common stock in direct ownership. The filing is made as a Form 4, which reports changes in insider ownership for officers, and confirms Nicholson’s role as Chief Technical Officer of Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Chief Financial Officer Timothy Sullivan reported a sale of company common stock. On January 13, 2026, he sold 3,856 shares at a price of $22.1872 per share, a transaction code "S". According to the footnotes, these shares were sold solely to cover tax withholding related to restricted stock units that were released on January 12, 2026, rather than as a discretionary open-market sale.
After this transaction, Sullivan directly held 107,080 shares of Apellis common stock. In addition, 60,396 shares are held indirectly by The Timothy E Sullivan Irrevocable Trust of 2023. A separate footnote explains that Patrick O. Collins is the trustee of this trust and that Sullivan disclaims beneficial ownership of those trust-held shares except to the extent of his pecuniary interest in them.
Apellis Pharmaceuticals General Counsel David O. Watson reported a small open-market sale of company stock. On January 13, 2026, he sold 5,780 shares of common stock at a price of $22.1872 per share under transaction code "S". The footnotes explain this sale was made to cover tax withholding on restricted stock units that were released on January 12, 2026.
After the sale, Watson beneficially owned 98,838 Apellis common shares directly. He also had indirect holdings of 10,000 shares in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, where he disclaims beneficial ownership except for any pecuniary interest.
Apellis Pharmaceuticals has a shareholder planning to sell 2618 shares of common stock under Rule 144. The shares are to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of 58086.09, on or about 01/13/2026 on the NASDAQ exchange. The filing notes that 126525218 shares of the issuer’s stock are outstanding. The 2618 shares being sold were acquired on 01/12/2026 through restricted stock vesting from the issuer as compensation, indicating they are newly vested shares now eligible for resale under Rule 144.
Apellis Pharmaceuticals shareholder files notice to sell restricted stock. A holder of Apellis common shares filed a Form 144 to potentially sell 873 shares of common stock through Fidelity Brokerage Services LLC on or about 01/13/2026, with the shares listed on NASDAQ. The shares have an aggregate market value of $19,369.43, compared with 126,525,218 common shares outstanding. These securities were acquired on 01/12/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 01/12/2026.
Apellis Pharmaceuticals insider David O. Watson filed a notice of proposed sale of 5,780 common shares under Rule 144. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ around 01/13/2026, with an indicated aggregate market value of
The 5,780 shares were acquired on 01/12/2026 through restricted stock vesting from the issuer as compensation. The notice also lists prior sales by Watson over the past three months, including three separate sales of 5,000 common shares each on 10/16/2025, 11/17/2025, and 12/16/2025 with gross proceeds of
FAQ
What is the current stock price of Apellis Pharmace (APLS)?
What is the market cap of Apellis Pharmace (APLS)?
